HighMark Wealth Management’s Viking Therapeutics VKTX Stock Holding History

HighMark Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$207K	Hold	5,310	–	–	0.07%	81
2026 Q1	$173K	Hold	5,310	–	–	0.07%	82
2025 Q4	$187K	Hold	5,310	–	–	0.08%	80
2025 Q3	$140K	Sell	5,310 -1,350	-20%	-$40.3K	0.06%	96
2025 Q2	$176K	Buy	6,660 +2,000	+43%	+$52.6K	0.09%	81
2025 Q1	$113K	Buy	4,660 +400	+9%	+$12.6K	0.07%	83
2024 Q4	$171K	Buy	4,260 +1,260	+42%	+$71.8K	0.1%	59
2024 Q3	$190K	Buy	+3,000	New	+$176K	0.1%	69

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

HighMark Wealth Management's VKTX Position: Q2 2026 in Review

HighMark Wealth Management held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 5,310 shares worth $207K. The position accounts for 0.07% of the portfolio, ranked #81.

HighMark Wealth Management first reported a position in VKTX in Q3 2024 and has held it in 8 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

HighMark Wealth Management held 5,310 shares of Viking Therapeutics worth $207K as of Q2 2026.
HighMark Wealth Management left its Viking Therapeutics share count unchanged in Q2 2026.
Viking Therapeutics made up 0.07% of HighMark Wealth Management's portfolio in Q2 2026, its #81 holding.
HighMark Wealth Management first reported a position in Viking Therapeutics in Q3 2024 and has held it in 8 quarters since.
436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.